key: cord-0901315-uj0csvt8
authors: Demirtas, Coskun Ozer; Keklikkiran, Caglayan; Ergenc, Ilkay; Erturk Sengel, Buket; Eskidemir, Gunes; Cinel, Ismail; Odabasi, Zekaver; Korten, Volkan; Yilmaz, Yusuf
title: Liver stiffness is associated with disease severity and worse clinical scenarios in coronavirus disease 2019: A prospective transient elastography study
date: 2021-05-29
journal: Int J Clin Pract
DOI: 10.1111/ijcp.14363
sha: 322ea7ef0bbf54baac3010672de997b06758cb49
doc_id: 901315
cord_uid: uj0csvt8

BACKGROUND: Pre‐existing chronic liver disease is currently considered a poor prognostic factor for coronavirus disease 2019 (COVID‐19). The present study aimed to investigate the association of liver stiffness measurement (LSM) with disease severity and clinical course of COVID‐19. METHODS: We prospectively recruited consecutive hospitalised adult patients with COVID‐19 in a 3‐month period. Demographic, laboratory, clinical and vibration‐controlled transient elastography (VCTE) features were recorded at entry, and all patients were prospectively followed‐up. Severe liver fibrosis was defined as an LSM value higher than 9.6 kPA. Multivariate logistic regression analysis was performed to reveal factors associated with disease severity and outcomes. RESULTS: Out of 98 eligible patients with COVID‐19, 12 (12.2%) had severe liver fibrosis. Patients with severe liver fibrosis had higher baseline disease severity (P = .022), more commonly required oxygen treatment at entry (P = .010), and had intensive‐care unit (ICU) requirements during the 6 (1‐39)‐day median follow‐up time (P = .017). The presence of severe liver fibrosis was independently associated with disease severity (odds ratio (OR): 7.685, 95% confidence interval (CI): 1.435‐41.162, P = .017) and ICU requirement (OR: 46.656, 95% CI: 2.144‐1015.090, P = .014). LSM was correlated with alanine aminotransferase levels (P = .005, r: 0.283), but not with other markers of acute hepatic injury or inflammation. CONCLUSION: Initial VCTE application might help physicians identify patients who are more likely to have severe illness or worse clinical outcomes, in addition to other well‐established clinical and laboratory factors. Further multicentre prospective studies are warranted to validate our results.

chronic lung disease (chronic obstructive pulmonary disease and asthma), male sex, and older age. 6 Several laboratory features have also been associated with worse clinical outcomes in COVID-19, most remarkably the presence of lymphopenia and increased Creactive protein. 7, 8 Despite these consistent factors associated with severe COVID-19, the impact of chronic liver disease on disease severity and progression has remained dubious. The observed increases in transaminase levels have been interpreted as hepatic injury of severe COVID-19 in several reports. 9 However, the aetiology of assumed liver damage remains unclear and is reported to be clinical of little concern. 10-12 Nevertheless,

there are a few studies in the literature demonstrating a strong association of liver injury and/or pre-existing liver disease with COVID-19 outcomes, [13] [14] [15] [16] but a recent pooled analysis of the accumulated literature has shown the opposite findings, 17 which was supported by the ensuing studies as well. 18 In general, having chronic liver disease is associated with increased severity and mortality for all-type pneumonias. 19, 20 Nevertheless, the role of liver disease or injury in COVID- 19 Previous studies have demonstrated that non-invasive liver fibrosis indicators, including FIB-4 index and neutrophil to lymphocyte ratio, are associated with poor clinical outcomes in COVID-19. [21] [22] [23] [24] [25] [26] Based on the evidence from these recent studies, it is rational to anticipate that patients with fibrosing NAFLD could be more prone to more severe COVID- 19 . In this regard, we aimed to confirm this hypothesis by investigating the associations of liver stiffness measurement (LSM) determined via vibration-controlled transient elastography (VCTE) (FibroScan; Echosens, Paris, France); which is a simple, reliable, and non-invasive ultrasound-based procedure to assess the severity of liver fibrosis, 27 with disease severity and clinical outcomes.

We prospectively recruited 98 consecutive adult inpatients with SARS-CoV-2 infection from Marmara University Hospital from June to September 2020. SARS-CoV-2 infection was documented by reverse-transcription polymerase chain reaction (PCR) assays of nasopharyngeal swab specimens in all patients. Patients were excluded if they met one of the following criteria: (a) younger than the age of 18, (b) pre-existing chronic liver disease (determined by the history and review of past laboratory results and/or abdominal ultrasound), (c) presence of ascites, (d) pregnancy, (e) history of liver transplantation, (f) significant alcohol consumption (≥20 g per week for women and ≥30 g per week for men) or (g) unable to give written informed consent. All demographic, laboratory, and clinical parameters were collected on the day of VCTE application. Eligible patients were confirmed to have negative hepatitis B surface antigen and anti-hepatitis C virus antibody results the day after VCTE application.

A total of 98 subjects without COVID-19 were separately recruited as a control cohort for the study (1:1) during their medical check-up programme in our hospital for the comparison of previously unknown non-alcoholic fatty liver disease (NAFLD) presence and LSM levels. The exclusion criteria used for COVID-19 patients were also implemented to control group candidates for eligibility in the study. The control group was constructed on two bases: (a) their comorbidities and habits were the representative of the general Turkish population;

and (b) they were matched with the COVID-19 group in terms of age, sex, presence of diabetes mellitus, and hyperlipidaemia. The data collection protocol of controls was similar to that of COVID-19 patients on the day of VCTE application.

The study protocol was approved by the local research ethical review board of the Marmara University School of Medicine (Approval date: 01.06.2020, Approval No: 09.2020.574). The study was performed in accordance with the principles of the Helsinki Declaration.

All participants provided written informed consent.

Elevated transaminase levels were defined as alanine aminotransferase (ALT) > 32.1 U/L for men and >23. 15 population, 28 which was also consistent with the previous cut-off values extracted from Asian populations. 29, 30 Obesity was defined as body mass index (BMI) ≥ 30 kg/m 2 . Diabetes mellitus was diagnosed based on history or haemoglobin A1c ≥ 6.5%. Hypertension was defined as blood pressure ≥ 130/85 mm Hg or specific drug use. Hyperlipidaemia was defined as total cholesterol higher than 200 ng/mL or low-density lipoprotein higher than 140 ng/mL. Other comorbidities were obtained from the patient's medical history. The presence of any coronary, organic heart disease or arrhythmia was defined as heart disease. The presence of chronic obstructive pulmonary disease (COPD) and/or asthma was defined as chronic lung disease. Immunosuppression was defined as a history of malignancy requiring chemotherapy in the past year or active usage of an immunosuppressive drug.

The hospitalisation time was calculated starting from the hospitalisation day to discharge or death. Chest involvement was categorised according to a visual quantitative evaluation of chest computed tomography (CT) imaging, as published. 31 All patients were classified for COVID-19 severity according to World Health Organization (WHO) clinical progression scale. 32 Severe disease was used to define patients with a WHO clinical progression scale score higher than 5, which corresponds to those requiring oxygen therapy. 

LSM and controlled-attenuation parameter (CAP) were both measured using a FibroScan® 530 compact device equipped with both M and XL probes by a physician trained and certified by the manufacturer at the beginning of hospitalisation. 33 All patients were asked to fast for at least 3 hours before the examination as per the manufacturer's instructions. Probe selection was performed using the automatic probe selection tool embedded in the device software. For the examination, the patients were placed in the dorsal decubitus position and the transducer probe was positioned in the intercostal space of the right lobe of the liver. Reliable VCTE measurements were defined as at least 10 valid measurements and having an interquartile-range-to-median ratio of ≤0.3. 34 CAP is an average estimate of ultrasound attenuation at 3.5 MHz and is expressed in dB/m. LSM is an average estimate of stiffness (Young's modulus) at a shear wave frequency of 50 Hz and is expressed as kPa. 35 Severe liver fibrosis (fibrosis ≥ 3) was defined as LSM higher than 9.6 kPA, as published several times. 27, 36, 37 Patients with hepatic steatosis were defined by a CAP value of ≥274 dB/m, and they were diagnosed with NAFLD owing to the exclusion of both secondary causes and significant daily alcohol consumption. 38,39

Descriptive statistics were used to describe the general characteristics of the study population. Continuous data are displayed as the mean ± standard deviation (SD) or median (minimum-maximum) when appropriate, and the distribution normality of the variables was assessed with the Kolmogorov-Smirnov or Shapiro-Wilk test.

Categorical data are expressed as counts and proportions. For the comparison of continuous variables between two groups, Student's t-test was used when the data conformed to a normal distribution;

otherwise, the Mann-Whitney U test was used. The chi-square test was used to compare categorical parameters. To reveal the association of LSM with disease outcomes, we performed multivariate logistic regression analysis with forward stepwise selection using the significant parameters (P < .05) from the univariate analysis and the well-acknowledged prognostic parameters for COVID-19 described in the literature. All variables were checked for multicollinearity by correlation coefficients to determine eligibility for multivariate analysis. When multicollinearity was detected between two parameters, only the parameter with the highest odds ratio in the univariate logistic regression analysis was included in the multivariate model to prevent estimation bias. Spearman's rho test was performed to investigate the possible correlations between LSM and markers of acute hepatic injury (AST and ALT) and inflammation (ferritin and C-reactive protein). Statistical significance was defined as P < .05.

All statistical analyses were conducted using SPSS software version 20.0 (IBM, Armonk, NY, USA).

Baseline demographics and VCTE characteristics are displayed in Table 1 . The mean age of the whole cohort was 55.2 ± 13.9 years.

Out of 98 patients with SARS-CoV-2 infection, 12 (12.2%) had severe liver fibrosis (LSM ≥ 9.6 kPA). Patients with severe liver fibrosis had a higher BMI (P = .028) and more commonly had diabetes mellitus (P = .015). There were no other differences between severe and non-severe liver fibrosis patients regarding other types and numbers of comorbidities. The median LSM of the whole cohort was 5.8 (2.6-16.1) kPA, and the mean CAP value was 261.2 ± 57.6 dB/m. Patients with severe liver fibrosis had higher leukocyte counts, lactate dehydrogenase, fibrinogen, and C-reactive protein levels and maximum ALT levels (all P values < .05). Forty-nine (50%) patients had high transaminase-elevated liver enzymes at entry. The laboratory characteristics are detailed in Table 2 .

COVID-19-related clinical characteristics and outcomes are shown in Table 3 . The median onset of COVID-19 symptoms before ad- was more common in patients with severe liver fibrosis than in those without severe fibrosis. We were not able to perform mortality analyses because of the low number of deaths.

There was bivariate collinearity between LSM, BMI, and ALT levels (all P-values < .05). Therefore, only LSM was included in the multivariate logistic regression analysis to prevent biased estimation and COVID-19 (n = 98) LSM < 9.6 (n = 86) LSM ≥ 9.6 (n = 12) P LSM was only correlated with ALT levels (P = .005, r: 0.283), and no correlation was observed with AST (P = .097, r: 0.168) and inflammatory markers, such as CRP (P = .075, r: 0.182) and ferritin (P = .160, r: 0.144).

The demographic and VCTE-related characteristics of the controls and COVID-19 patients are displayed in Supplementary 

In the present study, we reported an association of LSM determined previous study that investigated the association of LSM determined by VCTE with the COVID-19 disease course. The prior study consisted of only 32 patients, which is approximately one-third of our cohort, and therefore lacked an adequate number of patients to reach statistical power. 40 Nevertheless, that study found associa-

of the length of hospitalisation, the requirement of ICU treatment, and even mortality. However, these associations were only found in univariate analyses, and they were not able to show whether LSM is an independent factor associated with these outcomes. One other criticism for the prior study is the cut-off selection of LSM as 5.0 kPa, which is very low for reflecting significant (the generally accepted LSM cut-off is 7.2 to 7.5 kPa) or severe fibrosis (the generally accepted LSM cut-off is 9.6 kPa). In our study, we performed the same analysis with LSM cut-off values of 5 and 7.5 kPa and could not demonstrate any association with COVID-19 outcomes in multivariate analysis (data not presented). That is, we demonstrated that an LSM cut-off value of 9.6 kPa is the most appropriate threshold to predict worse COVID-19 outcomes.

A few studies have reported that patients with severe COVID-19

were more likely to have NAFLD than those with non-severe COVID-19 disease. [41] [42] [43] However, the prognosis of NAFLD is determined by the severity of liver fibrosis. 44 In this regard, a recent study Non-alcoholic steatohepatitis (NASH), which is severe form of NAFLD, was shown to have a strong association with the risk of COVID-19 in a population-based study from the United States. 47 The association of NASH presence and worse clinical outcomes in COVID-19 is rational, as circulating inflammatory markers are more pronounced in patients with NASH than in those with simple steatosis or without steatosis. However, we need more proof and explanation of whether the existence of NAFLD or NASH is associated with a higher incidence of COVID-19. As an additional analysis, we compared the VCTE results of our COVID-19 patients with those of a separate control group without COVID-19 (n = 98) and found slightly increased rates of previously unknown NAFLD presence in COVID-19 patients than in controls, although the difference was not significant. The median LSM value was higher in patients with COVID-19, which raised the question of whether this could be a reflection of COVID-19-related acute hepatic inflammation. In fact, this outcome was more likely the reflection of a higher obesity rate in the COVID-19 group. Studies investigating the association of biopsyproven NASH with COVID-19 with larger and better-matched prospectively followed cohorts are needed to clarify this issue.

The severe liver fibrosis rate of 12% detected in our study is conspicuously higher than the prevalence estimates (2%) reported in a large Asian population-based study using the same LSM cut-off value. 48 This discrepancy initially raises the suspicion of a selection bias, however, this is most likely caused by the fact that our cohort consisted of hospitalised patients for COVID-19 with several comorbidities while that prevalence study was representative of the normal healthy population in Hong-Kong Chinese. It is also possible 55 Similarly, men are considered more prone to COVID-19 disease as well as poorer prognosis. 56 In our study, we found no gender disparity regarding the disease severity and clinical outcomes.

Our study has several limitations. First, the lack of a large sample size prevented us from performing further subgroup analysis.

Nevertheless, this is the largest study to investigate the association of LSM determined by VCTE with COVID-19 disease severity and outcomes. Second, the exclusion of BMI as a covariable from multivariate analysis because of its multicollinearity with LSM might be considered a confounding condition. Obesity has been shown to be strongly associated with increased COVID-19 mortality and severity. 57 It provides a unique microenvironment for the pathogenesis of the disease and is characterised by a chronic, lowinflammatory state, which may lead to the production of exhausted immune cells, and the organism becomes more vulnerable to infections and less responsive to antimicrobial drugs. When obesity was added to other covariables for multivariate logistic regression analysis, we found that the significance of factors associated with disease severity and ICU requirement did not change, and obesity was amongst them; however, the odds ratios did change (data not presented). In this regard, we presented the multivariate analysis, as in the present results, to prevent estimation bias because of the coexistence of linear parameters and to give a more accurate risk increase of outcomes for each factor. Finally, although this was a prospective follow-up study, we could not perform a control VCTE after recovery, which could have provided information on whether the increased LSM was temporary because of acute COVID-19 infection or a permanent state. Nevertheless, the lack of a correlation between LSM and inflammatory markers prohibited us from interpreting such a potential association of LSM with acute liver injury in COVID-19.

In conclusion, LSM determined by VCTE is a useful parameter to reflect disease severity and is associated with ICU requirements for patients with COVID-19. Initial bedside LSM determined by VCTE might help physicians identify COVID-19 patients with higher susceptibility to worse clinical scenarios, in addition to other wellestablished clinical and laboratory factors. Further multicentre studies from different regions are warranted to validate our results.

Yusuf Yilmaz has served as a speaker for Gilead, Echosens, Bilim Pharmaceuticals, and advisory board member for Novonordisk, and has received research funding from Biocodex, Gilead. Other authors declare no conflict of interest.

Data available on request from the authors.

A novel coronavirus from patients with pneumonia in China

Coronavirus disease (COVID-19) and the liver: a comprehensive systematic review and meta-analysis

Gastrointestinal manifestations of SARS-CoV-2 infection and virus load in fecal samples from a Hong Kong cohort: systematic review and meta-analysis

Increased vulnerability to COVID-19 in chronic kidney disease

Subclinical acute kidney injury in COVID-19 patients: a retrospective cohort study

Clinical, laboratory and imaging features of COVID-19: a systematic review and meta-analysis

Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study

Lymphopenia predicts disease severity of COVID-19: a descriptive and predictive study

Liver injury during highly pathogenic human coronavirus infections

COVID-19 and the liver: little cause for concern

Editorial: intended victim or innocent bystander? The liver in COVID-19

Liver injury in COVID-19: the current evidence

Liver impairment associated with disease progression in COVID-19 patients

Impact of COVID-19 on liver function: results from an internal medicine unit in Northern Italy

Pre-existing liver disease is associated with poor outcome in patients with SARS CoV2 infection

APASL COVID-19 Liver Injury Spectrum Study)

Clinical characteristics and outcomes of coronavirus disease 2019 among patients with preexisting liver disease in the United States: a multicenter research network study

Chronic liver disease is not associated with severity or mortality in Coronavirus disease 2019 (COVID-19): a pooled analysis

Liver involvement is not associated with mortality: results from a large cohort of SARS-CoV-2 positive patients

High mortality of pneumonia in cirrhotic patients with ascites

Impact of chronic liver disease in intensive care unit acquired pneumonia: a prospective study

Detrimental effects of metabolic dysfunction-associated fatty liver disease and increased neutrophil-to-lymphocyte ratio on severity of COVID-19

Metabolic dysfunction associated fatty liver disease increases risk of severe Covid-19

Nonalcoholic fatty liver disease is associated with COVID-19 severity independently of metabolic syndrome: a retrospective case-control study

Risk of severe illness from COVID-19 in patients with metabolic dysfunction-associated fatty liver disease and increased fibrosis scores

Liver fibrosis index FIB-4 is associated with mortality in COVID-19

Elevation of liver fibrosis index FIB-4 is associated with poor clinical outcomes in patients with COVID-19

Determination of the upper limits of normal serum alanine aminotransferase (ALT) level in healthy Turkish population

Revising the upper limit of normal for levels of serum alanine aminotransferase in a Middle Eastern population with normal liver histology

Estimation of the healthy upper limits for serum alanine aminotransferase in Asian populations with normal liver histology

CT image visual quantitative evaluation and clinical classification of coronavirus disease (COVID-19)

Characterisation WHOWGotC, Management of C-i. A minimal common outcome measure set for COVID-19 clinical research

Transient elastography: a new noninvasive method for assessment of hepatic fibrosis

Arterial stiffness is associated independently with liver stiffness in biopsy-proven nonalcoholic fatty liver disease: a transient elastography study

FibroScan-AST (FAST) score for the non-invasive identification of patients with non-alcoholic steatohepatitis with significant activity and fibrosis: a prospective derivation and global validation study

Noninvasive assessment of liver fibrosis by measurement of stiffness in patients with chronic hepatitis C

Prospective comparison of transient elastography, Fibrotest, APRI, and liver biopsy for the assessment of fibrosis in chronic hepatitis C

Accuracy of FibroScan controlled attenuation parameter and liver stiffness measurement in assessing steatosis and fibrosis in patients with nonalcoholic fatty liver disease

European Association for the Study of the L, European Association for the Study of D, European Association for the Study of O. EASL-EASD-EASO Clinical Practice Guidelines for the management of non-alcoholic fatty liver disease

Liver stiffness by transient elastography accompanies illness severity in COVID-19

Non-alcoholic fatty liver diseases in patients with COVID-19: a retrospective study

Metabolic associated fatty liver disease increases the severity of COVID-19: A metaanalysis

MAFLD in COVID-19 patients: an insidious enemy

Association between fibrosis stage and outcomes of patients with nonalcoholic fatty liver disease: a systematic review and meta-analysis

Clinical utility of noninvasive scores in assessing advanced hepatic fibrosis in patients with type 2 diabetes mellitus: a study in biopsy-proven non-alcoholic fatty liver disease

Simple noninvasive scores are clinically useful to exclude, not predict, advanced fibrosis: a study in Turkish patients with biopsyproven nonalcoholic fatty liver disease

The incidence of COVID-19 in patients with metabolic syndrome and non-alcoholic steatohepatitis: a population-based study

Prevalence of non-alcoholic fatty liver disease and advanced fibrosis in Hong Kong Chinese: a population study using proton-magnetic resonance spectroscopy and transient elastography

Diagnostic accuracy of FibroScan and factors affecting measurements. Diagnostics (Basel)

COVID 19 and liver: An A-Z literature review

Manifestations and prognosis of gastrointestinal and liver involvement in patients with COVID-19: a systematic review and meta-analysis

Involvement of liver in COVID-19: systematic review and meta-analysis

Gastrointestinal complications in critically ill patients with and without COVID-19

Cardiac and muscle injury might partially contribute to elevated aminotransferases in COVID-19 patients

Sex and gender: modifiers of health, disease, and medicine

The physiological mechanisms of the sexbased difference in outcomes of COVID19 infection

Individuals with obesity and COVID-19: A global perspective on the epidemiology and biological relationships